There Are Only 3 Ways To Increase Your IGF-1 (How To Pick The Right One)

Your pituitary gland is the first domino in a chain that runs from your brain down to nearly every tissue in your body, and understanding that chain is what makes every growth hormone compound on the market make sense.

The chain works like this. A region of your brain called the hypothalamus releases something called GHRH, which stands for growth hormone-releasing hormone, and what it does is travel down to your pituitary and tell it to release growth hormone into your blood. That growth hormone then travels to your liver, where it triggers the production of something called IGF-1, which is insulin-like growth factor 1, and IGF-1 is the molecule that actually does the work: building tissue, burning fat, supporting recovery. The growth hormone number matters, but the IGF-1 number is what most people are really chasing.

Every compound in this space touches that chain at a different point. That is the entire framework.

The first category is GHRH analogs, which includes Tesamorelin, CJC-1295, and Sermorelin. These peptides mimic the signal your hypothalamus would normally send, so they tell your pituitary to release more of its own stored growth hormone. Your pituitary responds, your growth hormone rises, your liver converts it, and your IGF-1 climbs.

But your body is watching this happen. When IGF-1 rises high enough, your brain releases something called somatostatin, which acts like a brake on the pituitary. The higher your IGF-1 climbs, the harder somatostatin pushes back. This is called negative feedback, and it means these compounds have a built-in ceiling. You are working inside your body's own regulatory system, so the system will defend its upper limit. This is not a flaw in the compounds. It is just the biology. The ceiling also makes them the lower-risk path, and the right choice if your goal is restoring growth hormone output that has declined with age and supporting recovery, sleep quality, and fat loss without pushing past what your physiology would naturally allow.

The second category is exogenous growth hormone, meaning pharmaceutical HGH injected directly. When you inject growth hormone, you skip the pituitary entirely. The signal is not coming from inside the feedback loop. It is coming from outside it, which means the feedback loop is not controlling the dose the way it would with a GHRH analog.

This has a direct consequence. Research published in the Journal of Clinical Endocrinology and Metabolism showed that exogenous growth hormone suppresses the pituitary's own output. In one study, administering 20K growth hormone to healthy men reduced endogenous 22K growth hormone secretion measurably. Earlier work from Rosenthal and colleagues in 1986 confirmed the same mechanism: exogenous growth hormone inhibits the pituitary's response to GHRH. Your pituitary reads the elevated growth hormone in the blood, gets the same signal it would get from your hypothalamus, and pulls back its own production.

This is why stacking a GHRH analog on top of exogenous HGH does not work. If you are already injecting growth hormone, your pituitary is suppressed. Adding Tesamorelin or CJC-1295 is paying for a signal your body is already ignoring. The receptor is not listening.

Exogenous HGH is the path for sustained IGF-1 above your natural ceiling, and it requires ongoing use along with regular bloodwork to confirm your IGF-1 is staying in a productive range rather than climbing into territory where the risks start compounding.

The third category is IGF-1 LR3, which skips everything. You are not stimulating growth hormone production. You are not waiting for your liver to convert anything. You are injecting the downstream molecule directly. The LR3 modification extends the half-life of IGF-1 by reducing its binding to carrier proteins in the blood, which makes it more available to tissues for longer than natural IGF-1 would be.

Research from Chapman and colleagues showed that elevated IGF-1 directly suppresses growth hormone release, with free IGF-1 appearing to be the suppressive signal rather than bound IGF-1. IGF-1 LR3, because it binds poorly to those carrier proteins, keeps more of itself in the free fraction, which means it is both more active at tissues and more suppressive on the axis above it.

Because IGF-1 LR3 acts directly at the receptor level across tissues, receptor desensitization becomes a real concern. Running it continuously causes those receptors to downregulate, which is why cycling it at six to eight weeks is not optional. This is the highest-ceiling, highest-risk category, built for a specific short-term purpose with close monitoring.

Now the fat loss question, because this is where most of the confusion lives. Tesamorelin gets marketed as a visceral fat compound because that is what its clinical trials measured. The 2007 NEJM trial by Falutz and colleagues showed significant reductions in visceral adipose tissue in HIV patients using Tesamorelin. A 2015 review by Stanley and Grinspoon confirmed those effects across multiple human studies.

But the reason Tesamorelin reduces visceral fat is not because it has a unique mechanism that other compounds lack. It is because growth hormone-mediated lipolysis, the breakdown of fat driven by growth hormone signaling, preferentially targets visceral fat depots. Visceral fat has a higher density of growth hormone receptors than subcutaneous fat, so when growth hormone rises through any pathway, visceral fat responds first and most strongly. The 1997 study by Johannsson and colleagues showed this directly: growth hormone treatment in abdominally obese men reduced abdominal fat, improved lipid profiles, and lowered diastolic blood pressure, and that was exogenous GH, not Tesamorelin.

The mechanism is the same. The fat depot with the most receptors responds the most. Tesamorelin, Sermorelin, pharmaceutical HGH, and IGF-1 LR3 all drive this through the same pathway. As Moller and Jorgensen documented in their 2009 review of growth hormone's metabolic effects, GH increases lipolysis and free fatty acid availability across the board.

And none of it works without a calorie deficit. Growth hormone enhances the mobilization of stored fat. It does not override the basic energy equation.

The compounds are not interchangeable, but they are not mysteries either. They each enter the chain at a different point, and where they enter determines their ceiling, their risks, and their appropriate use. Once you know the chain, you know which entry point you need.

---

References

1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 357(23):2359-70. DOI: 10.1056/NEJMoa072375
2. Stanley TL, Grinspoon SK. (2015). Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res 25(2):59-65. DOI: 10.1016/j.ghir.2014.12.005
3. Moller N, Jorgensen JO. (2009). Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152-77. DOI: 10.1210/er.2008-0027
4. Hashimoto Y, Kamioka T, Hosaka M, Mabuchi K, Mizuchi A, Shimazaki Y, Tsunoo M, Tanaka T. (2000). Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men. J Clin Endocrinol Metab 85(2):601-6. DOI: 10.1210/jcem.85.2.6377
5. Rosenthal SM, Hulse JA, Kaplan SL, Grumbach MM. (1986). Exogenous growth hormone inhibits growth hormone-releasing factor-induced growth hormone secretion in normal men. J Clin Invest 77(1):176-83. DOI: 10.1172/JCI112273
6. Chapman IM, Hartman ML, Pieper KS, Skiles EH, Pezzoli SS, Hintz RL, Thorner MO. (1998). Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I: evidence for a suppressive action of free rather than bound IGF-I. J Clin Endocrinol Metab 83(8):2836-42. DOI: 10.1210/jcem.83.8.5040
7. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L, Bengtsson BA. (1997). Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82(3):727-34. DOI: 10.1210/jcem.82.3.3809

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness